VRTX Q3 2024 Earnings — Vertex Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena

VRTXVertex Pharmaceuticals Incorporated

$129B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2.8B+11.6% YoY

Gross Profit

$2.4B85.8% margin

Operating Income

$1.1B40.3% margin

Net Income

$1.0B37.7% margin

EPS (Diluted)

$4.01

QoQ Revenue Growth

+4.8%

Cash Flow

Operating Cash Flow

$1.4B

Free Cash Flow

$1.3B

Stock-Based Comp.

$185M

Balance Sheet

Total Assets

$22.2B

Total Liabilities

$6.6B

Stockholders' Equity

$15.6B

Cash & Equivalents

$5.2B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2.8B	$2.5B	+11.6%
Gross Profit	$2.4B	$2.2B	+9.9%
Operating Income	$1.1B	$1.0B	+7.5%
Net Income	$1.0B	$1.0B	+1.0%

Revenue Segments

TRIKAFTA/KAFTRIO

$2.6B93%

Manufactured Product, Other

$187M7%

Geographic Segments

UNITED STATES

$1.7B62%

Europe

$848M31%

Other, Non U.S.

$211M8%